Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Co-danthramer 37.5mg/500mg capsules
0106020B0AAAFAF
|
Co-danthramer | Co-danthramer (Dantron/poloxamer 188) | Gastro-Intestinal System | No data available |
|
Co-dergocrine mesilate 1.5mg tablets
0206040AMAAAAAA
|
Co-dergocrine mesilate | Co-dergocrine mesilate | Cardiovascular System | No data available |
|
Co-dergocrine mesilate 4.5mg tablets
0206040AMAAABAB
|
Co-dergocrine mesilate | Co-dergocrine mesilate | Cardiovascular System | No data available |
|
Co-dydramol 10mg/500mg oral powder sachets
0407010N0AAAFAF
|
Co-dydramol | Co-dydramol (Dihydrocodeine/paracetamol) | Central Nervous System | No data available |
|
Co-dydramol 7.46mg/500mg effervescent tablets sugar free
0407010N0AAAKAK
|
Co-dydramol | Co-dydramol (Dihydrocodeine/paracetamol) | Central Nervous System | No data available |
|
Co-fluampicil 125mg/125mg/5ml oral suspension
0501013L0AAADAD
|
Co-fluampicil | Co-fluampicil(Flucloxacillin/ampicillin) | Infections | No data available |
|
Co-fluampicil 250mg/250mg inj vials
0501013L0AAABAB
|
Co-fluampicil | Co-fluampicil(Flucloxacillin/ampicillin) | Infections | No data available |
|
Co-magaldrox 300mg/600mg tablets
0101010G0AAADAD
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | No data available |
|
Co-magaldrox 300mg/600mg/5ml oral suspension sugar free
0101010G0AAACAC
|
Co-magaldrox | Co-magaldrox (Magnesium/aluminium hydroxide) | Gastro-Intestinal System | No data available |
|
Co-methiamol 100mg/500mg tablets
040701020AAAAAA
|
Co-methiamol | Co-methiamol (Methionine/paracetamol) | Central Nervous System | No data available |
|
Co-prenozide 160mg/0.25mg modified-release tablets
0204000Y0AAAAAA
|
Co-prenozide | Co-prenozide (Oxprenolol hydrochloride/cyclopenthiazide) | Cardiovascular System | No data available |
|
Co-tenidone 100mg/25mg/5ml oral liquid
020400040AAACAC
|
Co-tenidone | Co-tenidone (Atenolol/chlortalidone) | Cardiovascular System | No data available |
|
Co-trimoxazole 160mg/800mg/10ml inf ampoules
0501080D0AAATAT
|
Co-trimoxazole | Co-trimoxazole(Trimethoprim/sulfamethoxazole) | Infections | No data available |
|
Co-trimoxazole 80mg/400mg/5ml solution for infusion ampoules
0501080D0AAABAB
|
Co-trimoxazole | Co-trimoxazole(Trimethoprim/sulfamethoxazole) | Infections | No data available |
|
Co-zidocapt 12.5mg/25mg tablets
0205051G0AAABAB
|
Co-zidocapt | Co-zidocapt (Hydrochlorothiazide/captopril) | Cardiovascular System | No data available |
|
CoaguChek PT testing strips
0208020W0BBAAA0
|
CoaguChek (Reagent) | INR blood testing reagents | Cardiovascular System | No data available |
|
Coal tar 0.5% in Yellow soft paraffin
1305020C0AAETET
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 1% in Aqueous cream
1305020C0AAEZEZ
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 1% in Emulsifying ointment
1305020C0AAGWGW
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 1% in Yellow soft paraffin
1305020C0AAEUEU
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 10% in Aqueous cream
1305020C0AAFAFA
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 10% in Clobetasol 0.05% ointment
1304000G0AADNDN
|
Clobetasol propionate | Clobetasol propionate | Skin | No data available |
|
Coal tar 10% in Generic Unguentum M cream
1305020C0AAFSFS
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar 10% in Hydrocortisone 1% cream
1305020I0AAANAN
|
Coal tar and corticosteroids | Coal tar and corticosteroid preparations | Skin | No data available |
|
Coal tar 10%/Salicylic acid 3% in Cetomacrogol (Formula A)
1305020C0AAGQGQ
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.